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Abstract
High-throughput post-genomic studies are now routinely and promisingly investigated in biological and biomedical
research. The main statistical approach to select genes differentially expressed between two groups is to apply a t-test,
which is subject of criticism in the literature. Numerous alternatives have been developed based on different and innovative
variance modeling strategies. However, a critical issue is that selecting a different test usually leads to a different gene list. In
this context and given the current tendency to apply the t-test, identifying the most efficient approach in practice remains
crucial. To provide elements to answer, we conduct a comparison of eight tests representative of variance modeling
strategies in gene expression data: Welch’s t-test, ANOVA [1], Wilcoxon’s test, SAM [2], RVM [3], limma [4], VarMixt [5] and
SMVar [6]. Our comparison process relies on four steps (gene list analysis, simulations, spike-in data and re-sampling) to
formulate comprehensive and robust conclusions about test performance, in terms of statistical power, false-positive rate,
execution time and ease of use. Our results raise concerns about the ability of some methods to control the expected
number of false positives at a desirable level. Besides, two tests (limma and VarMixt) show significant improvement
compared to the t-test, in particular to deal with small sample sizes. In addition limma presents several practical advantages,
so we advocate its application to analyze gene expression data.
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Introduction
During the last decade, advances in Molecular Biology and
substantial improvements in microarray technology have led
biologists toward high-throughput genomic studies. In particular,
the simultaneous measurement of the expression levels of tens of
thousands of genes has become a mainstay of biological and
biomedical research.
The use of microarrays to discover genes differentially expressed
between two or more groups (patients versus controls for instance)
has found many applications. These include the identification of
disease biomarkers that may be important in the diagnosis of the
different types and subtypes of diseases, with several implications
in terms of prognostic and therapy [7,8].
A first approach to identify differentially expressed genes is
known as the Fold-Change estimation (FC). It evaluates the
average log-ratio between two groups and considers as differen-
tially expressed all genes that differ by more than an arbitrary cut-
off. So defined, FC lacks of a solid statistical footing [9]: it does not
take the variance of the samples into account. This point is
especially problematic since variability in gene expression
measurements is partially gene-specific, even after the variance
has been stabilized by data transformation [10,11].
Rather than applying a FC cutoff, one should prefer statistical
tests: they standardize differential expression by considering their
variance [9,12]. Furthermore, corresponding effect sizes, confi-
dence intervals and p-values are essential information for the
control of false-positives [13] and meta-analysis [14].
The t-test is certainly the most popular test and has been matter
of discussion. Computing a t-statistic can be problematic because
the variance estimates can be skewed by genes having a very low
variance. These genes are associated to a large t-statistic and falsely
selected as differentially expressed [2]. Another drawback comes
from its application on small sample sizes which implies low
statistical power [12]. Consequently, the efficacy of a t-test along
with the importance of variance modeling have been seriously
called into question [15]. It has led to the development of many
innovative alternatives, with hope of improved variance estimation
accuracy and power.
These alternatives appear very diverse at a first sight, but fall
into few nested categories relying on both statistical and biological
hypotheses: parametric or non-parametric modeling, frequentist or
Bayesian framework, homoscedastic hypothesis (same variance
between groups of samples) and gene-by-gene variance estimation.
Further propositions come from the field of machine-learning for
instance [16], but lie beyond the scope of our study.
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different test usually identifies a different list of significant genes
since each strategy operates under specific assumptions [17].
Moreover, despite the wealth of available methods, the t-test
remains widely used in gene-expression studies, presumably
because of its simplicity and interpretability. Given the tendency
to use this method, identifying which approach is the most
appropriate to analyze gene expression data remains a crucial
issue. Nevertheless, if the development of new methodologies is still
an active topic of publication, only few studies have addressed
their comparison. This is probably due to the difficulty to
implement a realistic framework of comparison for which the
differentially expressed genes are known in advance.
In order to sidestep many problems, comparisons frequently
rely on the analysis of gene lists resulting from the application of
several methods [18] and simulations for which truly differentially
expressed genes are known [6]. More empirical alternatives
include the use of re-sampling methods (to compare genes from
small subsets of samples and those from the full dataset) [3,19], and
the use of spike-in data for which a set of genes are differentially
expressed by design [12,20]. Finally Jeffery et al. [18] explore an
indirect approach by assessing classification performance obtained
with genes resulting from the application of the methods to
compare. The heterogeneity of the strategies adopted in the
literature and the diversity of tests investigated make the
formulation of general conclusions difficult. In addition, to our
knowledge, no study has focused on the direct comparison of a
wide range of variance modeling strategies.
Consequently, we conduct a comparison study of eight tests
representative of variance modeling strategies in gene expression
data: Welch’s t-test, ANOVA [1], Wilcoxon’s test, SAM [2], RVM
[3], limma [4], VarMixt [5] and SMVar [6]. The comparison
process relies on four steps: gene list analysis, simulations, spike-in
data and re-sampling. Our aim is to benefit from the specificity of
each strategy, to make our results comparable to previous studies
and to ease the formulation of general, robust and reproducible
conclusions.
So defined, we follow a standard statistical framework. First, our
main focus concerns the issue of data reduction which relies on the
form of the test statistic and impact directly the resulting power. A
separate but important issue is calibration (i.e. the accuracy of
p-values) which can impact the false-positive rate (a). So at each
step of the process, tests are compared in terms of statistical power
assessed at the same false-positive rate. Control of the false-positive
rate to the desired value is checked for each test which is, to our
opinion, too rarely considered in the literature. Eventually, in
addition to an efficacy comparison, we find relevant to confront
each test in terms of practical consideration such as execution time
and ease of use.
Methods
Statistical background
Differential analysis consists in testing the null hypothesis (H0)
that the expected values of expression for a given gene are equal
between two groups of interest (1 and 2), against the alternative
hypothesis (H1) that they differ. Let Ygcr the level of expression
observed for gene g, replicate r, under group c; the general model
is then given by:
E(Ygcr)~mgc and Var(Ygcr)~s2
gc
So defined, the null hypothesis to test comes down to:
H0 : mg1~mg2
H1 : mg1=mg2
(
Given a statistical test, type-I error-rate a (resp. type-II error-rate
b) commonly refers to the probability to reject (resp. accept) H0,
H0 being true (resp. false). The statistical power of the test is then
defined as the ability to reject H0 when it is actually false:
Power(a)~PH1(H0 rejected at the a level)
~1{PH1(H0 not rejected at the a level)
~1{b
Type-I and II errors are inversely related: the smaller the risk of
one, the higher the risk of the other. Consequently the power
depends directly on a, and a valid comparison of several tests has
to be driven at the same type-I error-rate to overcome the issue of
calibration.
The type-I error-rate is often referred to as false-positive rate. It
differs from the false-discovery rate (FDR) in the sense that it
represents the rate that truly null features are called significant
whereas the FDR is the rate that significant features are truly null
[21].
Selection of the eight tests
This selection has focused on tests broadly applied in the
literature and representative of different variance modeling
strategies. The eight tests selected are described in detail in
Methods S1 and re-implemented in R to simplify their application.
The package is available on demand.
Briefly, most of the eight tests are parametric and estimate a
gene-by-gene variance: ANOVA (homoscedastic), Welch’s t-test
(heteroscedastic), RVM (homoscedastic), limma (homoscedastic
and based on a Bayesian framework) and SMVar (heteroscedastic
and based on structural model); we also select two non-parametric
approaches with the Wilcoxon’s test and the SAM test, which do
not rely on assumptions that the data are drawn from a given
probability distribution.
Besides, variances estimated on a set of genes are thought to
lead to an undesirable amount of false-positives. Attributing a
common variance to all the genes is clearly not a solution, even
when sample sizes are small. Several proposals make the
assumption that genes with the same expression level have
approximatively the same variance [22,23]. However this is not
realistic and also leads to false-positives [24]. We find VarMixt
more subtle: it makes the assumption that classes of genes can be
identified based on similar response to the various sources of
variability (mixture model); the variance of each homogeneous
class is then accurately estimated from a large set of observations;
the individual gene variance is then replaced by its ‘‘class’’
variance.
Comparison process
Gene list analysis. An intuitive first step to compare the tests
is to investigate the consistency between gene lists resulting from
the application of each test on real data. Here we apply this
approach to five publicly available data sets (Table 1) to assess the
overlap between gene lists and to identify similar behaviors among
the variance modeling strategies.
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draws for each gene a p-value from a Uniform distribution
between 0 and 1. Then, we applied the tests to the five data-sets to
identify gene differentially expressed by setting a p-value threshold
of 0:05.
Gene list similarities between tests are analyzed and visualized
using a Hierarchical Clustering (binary metric and the Ward’s
aggregation algorithm, R package stats) and Principal Component
Analysis (R package ade4 [25]). For more details please refer to
Methods S1 and Table S1.
Simulation study. The purpose of simulations is to estimate
power and false-positive rate on a large range of simulated data
sets, in order to compare the tests under simple and sometimes
extreme situations. We define a reference model (denoted M1),
frequently adopted in the literature and that matches the
assumptions of the t-test. Under M1, gene expressions for the
groups 1 and 2 are drawn from Gaussian distributions of same
variance (s~1):
Yg1r * N(mg1,s2)
Yg2r * N(mg2,s2)
(
Under H0: fmg1~mg2g while under H1: fmg2~mg1zdg, with
d~0:5.
Then, we propose three extensions of M1 (denoted M2, M3 and
M4) designed to be less to the t-test advantage. M2 is quite similar
but expression levels are now drawn from a Uniform distribution
of same parameters. M3 applies a mixture model on variances and
corresponds to the VarMixt hypothesis; genes are then divided
into three classes of variance. Under M4, 10% of the genes are
simulated with small variances (s2~0:05) since they can lead to an
increase of false-positive rate when the t-test is applied.
For each model we simulate 10,000 independent genes under
H0 to assess the false-positive rate attached to each test, and
10,000 under H1 to compute their respective power. False-positive
rate and power are both assessed at a p-value threshold of 0:05.
Sample size ranges from 5 to 100 samples per group. The
simulated data matrix is given Figure 1.
Spike-in data set. The Human Genome U133 data set is
used to test and validate microarray analysis methods (http://
www.affymetrix.com). The data set consists in 14 hybridizations of
42 spiked transcripts in a complex human background at
concentrations ranging from 0:125 pM to 512 pM. Each group
includes three replicates. We perform the 13 pairwise comparisons
for which ‘‘spike-in’’ genes have a true fold-change of two [5].
The whole data set contains 22,300 genes. The 42 spike-in
genes are designed to be differentially expressed (under H1) and
used for power estimation. To be able to compute the false-positive
rate, the 22,258 remaining genes are forced to be under H0 by
permutation of the group labels. False-positive rate and power are
both assessed at a p-value threshold of 0:05.
Re-sampling approach. The main idea is to assess the
ability of a test to select from small subsets of samples (n~5 and
n~10), genes determined as differentially expressed from the full
data set. The strategy can be summarized in four steps:
Step 1: From the 500 samples data set (Table 1) split into two
groups to compare, we define a set of differentially expressed genes
(p-valueƒ10{4 with the Welch’s t-test). This set is considered in
Step 3 as the ‘‘truth’’ to estimate power.
Step 2: n samples are drawn from each group and the eight tests
are performed on this subset of the initial data. We apply the
Benjamini and Hochberg correction at a 0:1 FDR level [31].
Step 3: From Step 2 we estimate power as the proportion of
genes defined as differentially expressed at Step 1 and detected at
Step 2.
Step 4: Steps 2 and 3 are iterated 1,000 times. Finally power is
averaged over the 1,000 iterations.
Results
Gene list analysis
Figure 2 represents PCAs and dendrograms resulting from gene list
analysis. The cumulative inertia explained by the two first axes of PCA
is about 80%. Both representations underline the same tendencies.
Table 1. Data sets used for the gene list analysis.
Data-set Groups Sample size Publication
Lymphoid
tumors
Disease staging 37 Lamant et al. 2007 [26]
Liver tumors TP53 mutation 65 Boyault et al. 2007 [27]
Head and
neck tumors
Gender 81 Rickman et al. 2008 [28]
Leukemia Gender 104 Soulier et al. 2006 [29]
Breast tumors ESR1 expression 500 Bertheau et al. 2007 [30]
The five data sets come from the Cartes d’Identite ´ des Tumeurs (CIT, http://cit.
ligue-cancer.net) program and are publicly available. All the microarrays are
Affymetrix U133A microarrays with 22,283 genes.
doi:10.1371/journal.pone.0012336.t001
Figure 1. Data matrix resulting from simulations. Rows refer to
genes simulated under H0 and H1, columns refer to samples of both
groups to compare.
doi:10.1371/journal.pone.0012336.g001
Should We Abandon the t-Test?
PLoS ONE | www.plosone.org 3 September 2010 | Volume 5 | Issue 9 | e12336As expected, gene lists resulting from the control-test are clearly
independent from the other ones, since it selects genes (differen-
tially expressed or not) uniformly. Then, the eight tests show
various behaviors. Six tests clusterize in two distinct groups: {t-test;
SMVar} and {VarMixt; limma; RVM; ANOVA}. The propor-
tion of common genes selected by two tests of the same cluster is
about 90%. On the other hand, Wilcoxon and SAM do not clearly
fall in one of the two main groups: Wilcoxon tends to consistently
lie between them, whereas SAM does not present a reproducible
behavior.
To summarize, homoscedastic (VarMixt, limma, RVM and
ANOVA), heteroscedastic (t-test and SMVar) variance modeling
strategies are well discriminated by a similarity analysis of gene
lists. It outlines the interesting property that similar modeling
strategies in theory imply similar results in practice.
Simulation study
First, we evaluate power according to sample size under the
simulation model M1 (Figure 3). On Figure 3-A, we notice little
difference between the tests (less than 0:08), particularly for large
samples as expected. Wilcoxon is not as good as the other tests in
most cases. SAM and ANOVA show equivalent performance to
the t-test. VarMixt, RVM and limma tend to provide an increase
in power, and SMVar slightly outperforms all the tests (Figures 3-
A and B).
As we know, these preliminary results are valid only if all the
tests meet the theoretical 5% false-positive rate when applying a
p-value threshold of 0:05. Table 2 gives the observed false-positive
rate for each test under small and large sample sizes and sheds
light on the fact that some tests clearly deviate from the 5% level
and return biased p-values. Observed deviations are more
accentuated for small sample sizes compared to large ones.
SMVar and RVM inflate the expected number of false-positives
whereas Wilcoxon and the t-test tend to be conservative; ANOVA,
SAM, limma and VarMixt show no deviation.
Regarding these observations, the tests inefficient to control the
false-positive rate at the expected 5% level have to be adjusted by a
time consuming Monte-Carlo procedure. Figures 3-C and D
present power results at adjusted and hence valid false-positive
rates. Differences are clearly reduced compared to Figures 3-A
and B which confirms that part of the difference in power observed
is due to actual difference in false-positive rate, particularly
concerning SMVar. After adjustment VarMixt, RVM and limma
tend to be the best tests although they provide an insignificant gain
compared to the t-test; Wilcoxon remains the less powerful.
ANOVA has performance comparable to the t-test which is
Figure 2. Gene list analysis. PCAs and dendrograms are generated based on the gene lists resulting from the application of the eight tests of
interest and the control-test. Here we show results for two data sets comparing ESR1 expression in breast cancer and gender in leukemia. Both
outline five clusters of tests.
doi:10.1371/journal.pone.0012336.g002
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that make the corresponding homoscedastic assumption (ANOVA)
do not show improved power compared to heteroscedastic ones
(Welch t-test).
Surprisingly, model M2 leads to the same conclusions (data not
shown). Here expression values follow a Uniform distribution
instead of a Gaussian one, which does not match the assumption of
parametric approaches. Compared to model M1, we were
expecting to note a more striking increase in power for Wilcoxon,
which is not observed. This result confirms that t-test and
assimilated approaches are quite robust to the Gaussian
assumption. Indeed the Central Limit Theorem implies that even
if expression values are not Gaussian, the t-statistic resulting from
the comparison of two groups is likely to be. It should be noticed
that the structural model of SMVar is not able to provide results
for the uniform model.
Finally models M3 and M4 also lead to the same conclusions,
with an overall loss of power (data not shown).
Spike-in data set
Spike-in data confirm observations and conclusions made on
the simulations. SMVar and RVM inflate the expected
number of false-positives whereas Wilcoxon and the t-test tend
to be conservative. Power values adjusted to a valid false-posi-
tive rate present more significant differences than in simula-
tions (Figure 4): with an average decrease of almost 0:6,
Wilcoxon is the less powerful and similar to the ‘‘control’’ test;
ANOVA shows equivalent performance than the t-test;
VarMixt, RVM, SMVar and limma provide a significant
increase in power with an average gain of 0:25.W i t h
performance comparable to the best tests, SAM has a different
behavior than in simulations.
Figure 3. Power study from simulations (Gaussian model, M1). Power values are calculated at the 5% level and displayed according to the
sample size. Figures A and C represent power values. Red arrows highlight the effect of false-positive rate adjustment on power values. Figures B and
D represent power values relative to t-test. Figures A and B concern power values calculated at the actual false-positive rate. Figures C and D concern
power values calculated at the adjusted false-positive rate.
doi:10.1371/journal.pone.0012336.g003
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This approach corroborates tendencies obtained with simula-
tions and spike-in data (Figure 5): limma, VarMixt and RVM
perform much better than other tests in identifying differentially
expressed genes, while SMVar is somewhat less efficient than the
three top-tests. ANOVA and the t-test still show equivalent
performance, although ANOVA presents here a slight but
significant improvement.
Wilcoxon and SAM were never able to detect genes determined
as differentially expressed. Indeed the calibration performed can
not reach p-value lower than 10{3 for small sample sizes. After the
Benjamini-Hochberg correction at a 0:1 FDR level (corresponding
here to a 10{6 p-value threshold), they do not detect any gene as
differentially expressed.
Practical comparison
Concerning time of execution and ease of use, the t-test and
ANOVA are the most efficient as they rely on standard statistical
considerations and have benefited of improved implementations.
On real high-throughput data, both take few seconds to treat tens
of thousands of genes. In terms of time of execution, limma
appears as efficient as the t-test and ANOVA, which is a
noteworthy point. SMVar, RVM and SAM run in longer but
still reasonable time (up to 8 minutes in our case). Varmixt turns
out to be the slowest approach (up to 80 minutes) as it relies on a
time consuming EM algorithm.
Discussion
Given the current tendency to apply the t-test to gene expression
data and the wealth of available alternatives, finding the most
appropriate approach to handle differential analysis is critical.
To address this problematic and provide some answers, we
develop a comparison process of eight tests for differential
expression. It is based on gene list analysis, simulations, spike-in
data and re-sampling, with the intention to benefit from the
specificity and advantages of each strategy.
Gene list analysis do not properly compare test performance
and hence lead to limited conclusions. However it is an
appropriate preliminary approach that focuses on similarities
between test results. An analysis of the consistency between gene
lists outlines general tendencies that can help in interpreting
differential analysis results. In our case, we observed comparable
results between tests based on similar variance modeling strategies.
The three other approaches (simulations, spike-in data and re-
sampling) propose a direct comparison of power values. Simula-
tions represent a convenient statistical framework as genes under
H0 and H1 are known in advance. In addition different hypotheses
on data structure can be specified under different simulation
models. Here, the three further models (M2, M3 and M4) lead
actually to the same conclusions than the reference Gaussian one
(M1). If simulations do not allow to observe significant differences
in power between the tests, they still reveal reproducible
tendencies. In addition, simulations turn out to be the gold
standard to check possible deviations from the expected false-
positive rate. However it is unclear whether simulated data sets
can sufficiently and realistically reflect the noise inherent in real
microarray data [32].
Table 2. False-positive rate study from simulations.
M1 M2 M3 M4
Sample size n~5n ~100 n~5n ~100 n~5n ~100 n~5n ~100
t-test
. 3:8{4:64 :5{5:44 :0{4:84 :6{5:53 :8{4:64 :7{5:63 :9{4:74 :4{5:3
ANOVA 4:5{5:24 :5{5:44 :7{5:64 :6{5:54 :5{5:44 :7{5:64 :5{5:34 :4{5:3
Wilcoxon
. 2:8{3:54 :6{5:52 :6{3:34 :5{5:42 :8{3:54 :7{5:62 :7{3:44 :5{5:4
SAM 4:6{5:54 :5{5:34 :2{5:14 :5{5:44 :7{5:64 :7{5:64 :3{5:24 :4{5:3
RVM
m 5:7{6:74 :5{5:45 :6{6:54 :5{5:45 :4{6:34 :7{5:65 :3{6:24 :7{5:5
limma 4:6{5:54 :6{5:54 :2{5:14 :5{5:44 :7{5:64 :7{5:64 :4{5:34 :3{5:1
SMVar
m 7:0{8:14 :7{5:6 {{5:9{6:84 :8{5:74 :6{5:54 :5{5:3
VarMixt 4:7{5:54 :6{5:54 :3{5:24 :6{5:54 :8{5:64 :6{5:54 :5{5:44 :5{5:3
For small and large samples, this table presents the 95% confidence-interval of false-positive rate obtained by applying a threshold of 0:05 to the p-values. Up triangles
m (resp. down triangles .) indicate an increase (resp. a decrease) of the false-positive rate compared to the expected level of 5%. Two triangles inform of a deviation in
both small and large sample sizes.
doi:10.1371/journal.pone.0012336.t002
Figure 4. Spike-in data set. Power values are calculated at the 5%
level and displayed according to six of the 13 pairwise comparisons.
doi:10.1371/journal.pone.0012336.g004
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re-sampling. Spike-in genes can represent gene expression better
than simulations. In our case it confirms conclusions from
simulations with more significant differences in power. Regarding
the Affymetrix data set we used, a criticism of this approach could
be that the small number of actual spike-in genes does not allow a
very accurate power estimation. Moreover variation across
technical replicates is likely to be lower than that typically
observed across true biological replicates, and many biological
effects of interest may be smaller than two-fold [12].
In this context, a re-sampling approach takes advantage of the
complexity found in real data. Differentially expressed genes are
not known but determined from a large data set (500 samples in
our case); power is then evaluated on a subset of the data. Results
are comparable to those obtained with simulations and spike-in
data. However this approach can be considered as limited in that it
assumes that gene lists generated on the full dataset are correct;
besides it is fastidious to implement and extremely time
consuming.
By applying four distinct comparison strategies with specific
advantages and drawbacks: (i) we ensure to offset the limitations
of each strategy and (ii) we provide robust conclusions on test
performance.
We applied this comparison process to eight tests representative
of different variance modeling strategies. Results are summarized
in Table 3. A first important result concerns the control of the
false-positive rate, which is often disregarded in the literature.
Under H0, distribution of p-values is supposed to be uniform and
the false-positive rate resulting from a p-value threshold of 0:05
should be controlled at 5%. Deviation from this major assumption
may indicate biased p-values. In both simulations and spike-in
data, some tests deviate from the expected false-positive rate,
which partly explains some differences in power (namely SMVar,
RVM and Wilcoxon). For the purpose of our study, we performed
a Monte-Carlo based adjustment of the false-positive rate to
formulate comparable conclusions across all the tests. However in
practice this adjustment remains fastidious to implement. In
consequence, we strongly advocate to avoid using these tests until
a proper corrected version is made available.
Overall, Wilcoxon and SAM show weak performance. One of
our simulation model (M2) clearly outlines the robustness of
parametric tests to the Gaussian assumption. Concerning SAM,
our results do not allow to formulate clear conclusions and reflect
existing doubts about its efficacy [18,33].
Compared to the t-test, limma and VarMixt consistently show
real improvement, in particular on small sample sizes. Limma has
often been discussed in the biostatistical field and its good
performance has been reported [12,18,24]. Surprisingly VarMixt
does not appear as weak as similar methods evaluated by
Kooperberg et al. [24]. Presumably it benefits from a more
realistic mixture model on variances, less likely to generate false-
positives.
If limma and VarMixt are equivalent regarding both power and
false-positive rate, in practice limma presents several further
advantages in terms of execution time. In addition, limma can be
generalized to more than two groups which makes it relevant to
many broader situations.
To conclude, we have developed a comprehensive process to
compare statistical tests dedicated to differential analysis. This
approach can be used as the basis to evaluate performance of
methods developed in the near future. In addition, to answer our
initial question ‘‘Should we abandon the t-test’’, limma provides a
Figure 5. Re-sampling approach. Power values are calculated at a 0.1 FDR level and displayed according to the sample size.
doi:10.1371/journal.pone.0012336.g005
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PLoS ONE | www.plosone.org 7 September 2010 | Volume 5 | Issue 9 | e12336substantial improvement compared to the t-test, particularly for
small samples. However the t-test remains easy to apply through a
wide-range of genomic analysis tools whereas limma can appear
more difficult to implement at a first sight. To promote its
application we make available on demand a simplified R version of
limma dedicated to the analysis of two groups of samples.
Supporting Information
Methods S1 A detailed description of (i) the eight tests included
in the study and (ii) the gene list analysis process.
Found at: doi:10.1371/journal.pone.0012336.s001 (0.09 MB
PDF)
Table S1 Example of binary matrix. For a given test, the genes
identified as differentially expressed (‘‘1’’) and not differentially
expressed (‘‘0’’) at a given p-value threshold are reported in the
binary matrix.
Found at: doi:10.1371/journal.pone.0012336.s002 (0.01 MB
PDF)
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